Subscribe to STAT+ and access exclusive benefits this month
When you're a STAT+ subscriber, you get to enjoy perks like discounts on our STAT Reports and events, free access to premium data tools like our CRISPR TRACKR, as well as in-depth daily coverage and analysis of the life sciences.
SUBSCRIBE
This report is an update of our best-seller, that breaks down the numbers and provides a ranked list for over a dozen of the biggest names in biotech venture capital. You'll learn which firms' portfolios have best weathered the economic storm, and which firms delivered the best returns to shareholders.
STAT+ subscribers get 20% off all STAT Reports.
PURCHASE
This collection of first-hand patient stories goes beyond the noise of the health care industry and highlights each patient's voice. Read valuable insights and lessons from 11 First Opinion articles that can help regulators, health care professionals, drug developers, and others set priorities, center the patient, and improve outcomes for future patients. Download this special report to explore how each person going through the health care system has their own expertise, humanity, and pain.
STAT+ subscribers get 20% off all STAT Reports.
Purchase
Date: October 18 - 19, 2023
Location: Boston, MA / Virtual
Explore what it takes to make health care function as a coherent system, from the early funding of new ideas to patients receiving the treatment they need. Over two full days of conversation, you'll learn from people working at different points in the system - researchers, academics, CEOs, investors, and patient advocates - and we'll look for solutions.
Subscribe to STAT+ to unlock a 20% on your ticket.
LEARN MORE
Date: September 5 - 7, 2023 from 1 – 3 p.m. ET each day
Location: Virtual
Can CAR-T revolutionize the way tumors are treated? What does it take to develop a vaccine? How has Ozempic changed the industry? Answer these questions, and look to what's next, with big name executives, global policymakers and more.
Subscribe to STAT+ for free access to this event!
LEARN MORE
STAT+ Reads
Check out our recent top stories:
READ MORE
No comments